1
|
Kim PJ, Yuan M, Wu J, Gallo L, Uhlman K, Voineskos SH, O’Neill A, Hofer SO. "Spin" in Observational Studies in Deep Inferior Epigastric Perforator Flap Breast Reconstruction: A Systematic Review. Plast Reconstr Surg Glob Open 2023; 11:e5095. [PMID: 37351115 PMCID: PMC10284325 DOI: 10.1097/gox.0000000000005095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2023] [Accepted: 04/26/2023] [Indexed: 06/24/2023]
Abstract
The deep inferior epigastric artery perforator (DIEP) flap is widely used in autologous breast reconstruction. However, the technique relies heavily on nonrandomized observational research, which has been found to have high risk of bias. "Spin" can be used to inappropriately present study findings to exaggerate benefits or minimize harms. The primary objective was to assess the prevalence of spin in nonrandomized observational studies on DIEP reconstruction. The secondary objectives were to determine the prevalence of each spin category and strategy. Methods MEDLINE and Embase databases were searched from January 1, 2015, to November 15, 2022. Spin was assessed in abstracts and full-texts of included studies according to criteria proposed by Lazarus et al. Results There were 77 studies included for review. The overall prevalence of spin was 87.0%. Studies used a median of two spin strategies (interquartile range: 1-3). The most common strategies identified were causal language or claims (n = 41/77, 53.2%), inadequate extrapolation to larger population, intervention, or outcome (n = 27/77, 35.1%), inadequate implication for clinical practice (n = 25/77, 32.5%), use of linguistic spin (n = 22/77, 28.6%), and no consideration of the limitations (n = 21/77, 27.3%). There were no significant associations between selected study characteristics and the presence of spin. Conclusions The prevalence of spin is high in nonrandomized observational studies on DIEP reconstruction. Causal language or claims are the most common strategy. Investigators, reviewers, and readers should familiarize themselves with spin strategies to avoid misinterpretation of research in DIEP reconstruction.
Collapse
Affiliation(s)
- Patrick J. Kim
- From the Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada
| | - Morgan Yuan
- Division of Plastic, Reconstructive and Aesthetic Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada
| | - Jeremy Wu
- Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
| | - Lucas Gallo
- Division of Plastic Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada
| | - Kathryn Uhlman
- Division of Plastic, Reconstructive and Aesthetic Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada
| | - Sophocles H. Voineskos
- Division of Plastic, Reconstructive and Aesthetic Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada
| | - Anne O’Neill
- Division of Plastic, Reconstructive and Aesthetic Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada
| | - Stefan O.P. Hofer
- Division of Plastic, Reconstructive and Aesthetic Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
2
|
Haykal S, Juvet S, Chan AW, O’Neill A, Pal P, Cypel M, Keshavjee S. Assessment of Acute Rejection in a Lung Transplant Recipient Using a Sentinel Skin Flap. Transpl Int 2023; 36:11166. [PMID: 37077407 PMCID: PMC10106558 DOI: 10.3389/ti.2023.11166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2023] [Accepted: 03/21/2023] [Indexed: 04/05/2023]
Affiliation(s)
- Siba Haykal
- Division of Plastic and Reconstructive Surgery, Department of Surgery, University Healthy Network, Toronto, ON, Canada
- *Correspondence: Siba Haykal,
| | - Stephen Juvet
- Division of Medicine, Division of Respirology, University Healthy Network, Toronto, ON, Canada
| | - An-Wen Chan
- Department of Dermatology, University Healthy Network, Toronto, ON, Canada
| | - Anne O’Neill
- Division of Plastic and Reconstructive Surgery, Department of Surgery, University Healthy Network, Toronto, ON, Canada
| | - Prodipto Pal
- Department of Pathology, University Healthy Network, Toronto, ON, Canada
| | - Marcelo Cypel
- Division of Thoracic Surgery, Department of Surgery, University Healthy Network, Toronto, ON, Canada
| | - Shaf Keshavjee
- Division of Thoracic Surgery, Department of Surgery, University Healthy Network, Toronto, ON, Canada
| |
Collapse
|
3
|
O’Neill A, Seidman J, Cavagnero K, Li F, Nakatsuji T, Cheng J, Tong Y, Do T, Cau L, Hata T, Modlin R, Gallo R. 349 Functional screening of Cutibacterium acnes isolates reveal determinants of skin inflammation. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.09.362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
4
|
Shulman Z, O’Neill A, Kouneli S, Shaaban A, Jenkins S. EP-276 Tall Cell Carcinoma with Reverse Polarity (TCCRP) of the breast; a rare form of breast cancer. Br J Surg 2022. [DOI: 10.1093/bjs/znac245.073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Abstract
Aim
A case report on the diagnosis and treatment of this rare low grade triple negative breast cancer.
Case Report
A 41 year old female presented with a palpable left breast lump. Family history includes a sister with a rare myeloproliferative disorder. On examination, a left breast lower outer quadrant 2–3 cm hard irregular lump was palpable. Mammography and ultrasound revealed a 25 mm suspicious lesion (which was biopsied), with normal appearing lymph nodes.
Results
Biopsy revealed a grade 2 invasive apocrine carcinoma. Oestrogen and Herceptin receptors negative. Breast conserving surgery with sentinel lymph node biopsy was performed. Histology revealed a 22 mm well circumscribed tumour with nests of epithelial cells in micropapillary pattern with apocrine like appearance. The most striking feature was that the nuclei were at the apical rather than the basal poles of the epithelial cells (reverse polarity). No lymphovascular invasion present. Lymph nodes were negative (0/3). Diagnosis was then confirmed by molecular testing.
Conclusion
Tall cell carcinoma with reverse polarity (TCCRP)1, a rare cancer resembling tall cell variant of papillary thyroid carcinoma, was first reported by Eusebi et al in 20032. Although morphologically similar to metastatic papillary thyroid cancer, neither the immunohistochemical markers nor genetic profiles have established any connection3. Accurate diagnosis of TCCRP is important as it carries an excellent prognosis. Treatment is local regional radiotherapy. There is no indication for systemic therapy in this case, due to its indolent low metastatic potential.
Collapse
|
5
|
Leahy A, Corey G, O’Neill A, Higginbotham O, Devlin C, Barry L, Cummins N, Shanahan E, Shchetkovsky D, Ryan D, O'Connor M, Galvin R. 1081 A COMPARISON OF THE ISAR TOOL AND THE CLINICAL FRAILTY SCALE TO PREDICT MORTALITY AND ED REATTENDANCE IN A COHORT OF ED ATTENDER. Age Ageing 2022. [DOI: 10.1093/ageing/afac126.086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Frailty Screening is one method by which we can risk stratify older adults to urgent assessment in the Emergency Department. The ISAR (Identification of Seniors at Risk) and Rockwood Clinical Frailty Scale are two frailty screening tools. We assessed the validity of these tools at predicting adverse outcomes for older adults presenting to the Emergency Department.
Method
This was a prospective cohort study. Patients over 65 were recruited, baseline.
demographics were obtained and a research nurse assessed them using both the Clinical Frailty Scale and ISAR. Patients were assessed by telephone interviews at one month and six months. The outcome measures assessed were mortality, ED re-attendance, hospital readmission, functional decline and institutionalisation.
Results
419 patients were recruited. 53.3% (223) were male with a median age of 76 (IQR = 10). The median ISAR and CFS score was 2,5 respectively at baseline. The mortality rate was 5.4% and rate of ED re-attendance was 16.9% at one month. The relative risk of ED re-admission with an ISAR score >/= 2 more was 1.84 (1.12, 3.02) and CFS > 4 was 1.85 (1.08, 3.16). The ISAR tool >/= 2, had a sensitivity of 74.29 (95% CI = 62.44, 83.99) and specificity of 41.18 (95% CI = 35.90, 46.61) when used as a diagnostic tool for ED re-admission at one month. The CFS > 4 had a sensitivity of 71.43 (95% CI = 57.79, 82.70) and specificity of 45.23 (95% CI = 39.33, 51.23) for the same outcome.
Conclusion
The ISAR tool >/= 2 was the more sensitive at predicting ED reattendance at one month in comparison to the Clinical Frailty Scale. We would advocate using this tool in the ED setting to highlight those at greatest risk of adverse outcomes and those most likely to benefit from Comprehensive Geriatric Assessment.
Collapse
Affiliation(s)
- A Leahy
- School of Allied Health , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
- University of Limerick , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
- Department of Ageing and Therapeutics, University Hospital Limerick , Limerick, Ireland
| | - G Corey
- School of Allied Health , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
- University of Limerick , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
| | - A O’Neill
- School of Allied Health , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
- University of Limerick , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
| | - O Higginbotham
- School of Allied Health , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
- University of Limerick , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
| | - C Devlin
- School of Allied Health , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
- University of Limerick , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
| | - L Barry
- School of Allied Health , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
- University of Limerick , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
- School of Nursing and Midwifery , Faculty of Education and Health Sciences, , Limerick, Ireland
- University of Limerick , Faculty of Education and Health Sciences, , Limerick, Ireland
| | - N Cummins
- School of Allied Health , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
- University of Limerick , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
| | - E Shanahan
- Department of Ageing and Therapeutics, University Hospital Limerick , Limerick, Ireland
| | - D Shchetkovsky
- Department of Emergency Medicine, University Hospital Limerick , Limerick, Ireland
| | - D Ryan
- Department of Emergency Medicine, University Hospital Limerick , Limerick, Ireland
| | - M O'Connor
- Department of Ageing and Therapeutics, University Hospital Limerick , Limerick, Ireland
| | - R Galvin
- School of Allied Health , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
- University of Limerick , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
| |
Collapse
|
6
|
Sparano JA, O’Neill A, Graham N, Northfelt DW, Dang CT, Wolff AC, Sledge GW, Miller KD. Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer. NPJ Breast Cancer 2022; 8:16. [PMID: 35136076 PMCID: PMC8825796 DOI: 10.1038/s41523-021-00376-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2021] [Accepted: 12/07/2021] [Indexed: 01/14/2023] Open
Abstract
Systemic inflammation is believed to contribute to the distant recurrence of breast cancer. We evaluated serum samples obtained at diagnosis from 249 case:control pairs with stage II-III Her2-negative breast cancer with or without subsequent distant recurrence. Conditional logistic regression analysis, with models fit via maximum likelihood, were used to estimate hazard ratios (HRs) and test for associations of cytokines with distant recurrence risk. The only biomarker associated with a significantly increased distant recurrence risk when adjusted for multiple testing was the proinflammatory cytokine IL-6 (HR 1.37, 95% confidence intervals [CI] 1.15, 1.65, p = 0.0006). This prospective-retrospective study provides evidence indicating that higher levels of the cytokine IL-6 at diagnosis are associated with a significantly higher distant recurrence risk.
Collapse
Affiliation(s)
- Joseph A. Sparano
- grid.59734.3c0000 0001 0670 2351Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY USA
| | - Anne O’Neill
- grid.65499.370000 0001 2106 9910Dana Farber Cancer Institute ECOG-ACRIN Biostatistics Center, Boston, MA USA
| | - Noah Graham
- grid.65499.370000 0001 2106 9910Dana Farber Cancer Institute ECOG-ACRIN Biostatistics Center, Boston, MA USA
| | | | - Chau T. Dang
- grid.51462.340000 0001 2171 9952Memorial Sloan Kettering Cancer Center, New York, NY USA
| | - Antonio C. Wolff
- grid.280502.d0000 0000 8741 3625Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD USA
| | - George W. Sledge
- grid.168010.e0000000419368956Stanford Cancer Center, Palo Alto, CA USA
| | - Kathy D. Miller
- grid.257413.60000 0001 2287 3919Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN USA
| |
Collapse
|
7
|
Rosenberg SM, O’Neill A, Sepucha K, Miller KD, Dang CT, Northfelt DW, Sledge GW, Schneider BP, Partridge AH. Quality of Life Following Receipt of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer. JAMA Netw Open 2022; 5:e220254. [PMID: 35226083 PMCID: PMC8886546 DOI: 10.1001/jamanetworkopen.2022.0254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
IMPORTANCE Breast cancer treatment can impact not only short-term health but may also affect longer-term quality of life (QOL). OBJECTIVE To describe and evaluate factors associated with diminished QOL following completion of active treatment. DESIGN, SETTING, AND PARTICIPANTS This was a secondary analysis of a randomized clinical trial included patients with lymph node-positive or high-risk lymph node-negative breast cancer who had undergone definitive surgery and were enrolled in ECOG-ACRIN E5103, a multisite phase 3 trial. A survey was administered 18 months after enrollment to patients enrolled between January and June 2010. Final analysis of the data took place from March to December 2021. INTERVENTIONS Patients received adjuvant doxorubicin, cyclophosphamide, and paclitaxel with either bevacizumab or placebo. MAIN OUTCOMES AND MEASURES QOL and health status assessed with the EuroQol 5-Dimension 3-Levels (EQ-5D-3L), EQ-visual analog scale (EQ-VAS), and the Functional Assessment of Cancer Therapy-Breast Cancer, with arm subscale (FACT-B+4). Groups were compared by Fisher exact test, Wilcoxon rank sum, or Kruskal-Wallis test. Multivariable linear regression was used to assess factors independently associated with FACT-B scores. RESULTS Data at 18 months were available from 455 of 519 patients (87.7%) enrolled in the trial. Median (range) age at enrollment was 52 (25-76) years. No differences in QOL (median [range] FACT-B scores: group A, 123 [67-146]; group B, 114 [54-148]; group C, 117 [42-148]; P = .23) or health status (median [range] EQ-5D-3L index scores: group A, 0.83 [0.28-1.00]; group B, 0.83 [0.20-1.00]; group C, 0.83 [0.17-1.00], P = .80; median EQ-VAS: group A, 85 [20-100]; group B, 85 [0-100]; group C, 85 [0-100]; P = .79) were observed across treatment groups; results for subsequent analyses were therefore reported irrespective of primary treatment. Overall, half of patients (258 of 444 [58%]) reported at least some pain or discomfort; 170 (38%) reported symptoms of anxiety or depression. In multivariable analyses, mastectomy with radiation (vs breast conserving surgery) and Asian, Black, or American Indian or Alaska Native race (vs White race) were associated with lower QOL (mastectomy with radiation: coefficient: -5.5; 95% CI, -10.1 to -0.9; Asian, Black, or American Indian or Alaska Native race: coefficient: -7.3; 95% CI, -13.2, -1.4). CONCLUSIONS AND RELEVANCE In this study, the addition of bevacizumab to chemotherapy was not negatively associated with QOL at 18 months. A substantial proportion of participants reported problems related to pain or discomfort and anxiety or depression, demonstrating persistent consequences for physical and psychosocial well-being in this heavily treated population. Many problems reported are amenable to intervention, underscoring the need for timely referral to supportive resources, especially for women of color and those who have more extensive local therapy. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT00433511.
Collapse
Affiliation(s)
| | - Anne O’Neill
- Dana-Farber Cancer Institute, Boston, Massachusetts
- ECOG-ACRIN Biostatistics Center, Boston, Massachusetts
| | | | | | - Chau T. Dang
- Memorial Sloan Kettering Cancer Center, New York, New York
| | | | - George W. Sledge
- Indiana University, Indianapolis
- Stanford University, Stanford, California
| | | | | |
Collapse
|
8
|
Lynch S, Varasteh M, Russell E, Harney J, Conkey D, Cole A, Osman S, Flannery T, Prise K, O’Neill A, McGarry C. PO-1031 Tumour volume influences local control and overall survival following Stereotactic Radiosurgery. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07482-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
9
|
Upshaw J, Ruthazer R, Miller K, Parsons S, Erban J, O’Neill A, Wagner L, Sledge G, Ky B, Kent D. A TOOL FOR PERSONALIZED DECISION MAKING: A CLINICAL PREDICTION MODEL FOR ANTHRACYCLINE CARDIOTOXICITY IN EARLY STAGE BREAST CANCER. J Am Coll Cardiol 2018. [DOI: 10.1016/s0735-1097(18)31237-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
10
|
Schneider BP, Shen F, Jiang G, O’Neill A, Radovich M, Li L, Gardner L, Lai D, Foroud T, Sparano JA, Sledge GW, Miller KD. Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-E5103. JCO Precis Oncol 2017; 2017:PO.17.00059. [PMID: 29333527 PMCID: PMC5765553 DOI: 10.1200/po.17.00059] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Racial disparity in breast cancer outcomes exists between African American and Caucasian women in the United States. We have evaluated the impact of genetically determined ancestry on disparity in efficacy and therapy-induced toxicity for breast cancer patients in the context of a randomized, phase III adjuvant trial. PATIENTS AND METHODS This study compared outcomes between 386 patients of African ancestry (AA) and 2473 patients of European ancestry (EA) in a randomized, phase III breast cancer trial; ECOG-ACRIN-E5103. The primary efficacy endpoint, invasive disease free survival (DFS) and clinically significant toxicities were compared including: anthracycline-induced congestive heart failure (CHF), taxane-induced peripheral neuropathy (TIPN), and bevacizumab-induced hypertension. RESULTS Overall, AAs had significantly inferior DFS (p=0.002; HR=1.5) compared with EAs. This was significant in the estrogen receptor-positive subgroup (p=0.03); with a similar, non-significant trend for those who had triple negative breast cancer (TNBC; p=0.12). AAs also had significantly more grade 3-4 TIPN (OR=2.9; p=2.4 ×10-11) and grade 3-4 bevacizumab-induced hypertension (OR=1.6; p=0.02), with a trend for more CHF (OR=1.8; p=0.08). AAs had significantly more dose reductions for paclitaxel (p=6.6 ×10-6). In AAs, dose reductions in paclitaxel had a significant negative impact on DFS (p=0.03); whereas in EAs, dose reductions did not impact outcome (p=0.35). CONCLUSION AAs had inferior DFS with more clinically important toxicities in ECOG-ACRIN-E5103. The altered risk to benefit ratio for adjuvant breast cancer chemotherapy should lead to additional research with the focus centered on the impact of genetic ancestry on both efficacy and toxicity. Strategies to minimize dose reductions for paclitaxel, especially due to TIPN, are warranted for this population.
Collapse
Affiliation(s)
- Bryan P. Schneider
- Bryan P. Schneider, Fei Shen, Guanglong Jiang, Milan Radovich, Lang Li, Laura Gardner, Dongbing Lai, Tatiana Foroud, and Kathy D. Miller, Indiana University School of Medicine, Indianapolis, IN; Anne O’Neill, Dana Farber Cancer Institute–ECOG-ACRIN Biostatistics Center, Boston, MA; Joseph A. Sparano, Albert Einstein University, Bronx, NY; and George W. Sledge Jr, Stanford University, Stanford, CA
| | - Fei Shen
- Bryan P. Schneider, Fei Shen, Guanglong Jiang, Milan Radovich, Lang Li, Laura Gardner, Dongbing Lai, Tatiana Foroud, and Kathy D. Miller, Indiana University School of Medicine, Indianapolis, IN; Anne O’Neill, Dana Farber Cancer Institute–ECOG-ACRIN Biostatistics Center, Boston, MA; Joseph A. Sparano, Albert Einstein University, Bronx, NY; and George W. Sledge Jr, Stanford University, Stanford, CA
| | - Guanglong Jiang
- Bryan P. Schneider, Fei Shen, Guanglong Jiang, Milan Radovich, Lang Li, Laura Gardner, Dongbing Lai, Tatiana Foroud, and Kathy D. Miller, Indiana University School of Medicine, Indianapolis, IN; Anne O’Neill, Dana Farber Cancer Institute–ECOG-ACRIN Biostatistics Center, Boston, MA; Joseph A. Sparano, Albert Einstein University, Bronx, NY; and George W. Sledge Jr, Stanford University, Stanford, CA
| | - Anne O’Neill
- Bryan P. Schneider, Fei Shen, Guanglong Jiang, Milan Radovich, Lang Li, Laura Gardner, Dongbing Lai, Tatiana Foroud, and Kathy D. Miller, Indiana University School of Medicine, Indianapolis, IN; Anne O’Neill, Dana Farber Cancer Institute–ECOG-ACRIN Biostatistics Center, Boston, MA; Joseph A. Sparano, Albert Einstein University, Bronx, NY; and George W. Sledge Jr, Stanford University, Stanford, CA
| | - Milan Radovich
- Bryan P. Schneider, Fei Shen, Guanglong Jiang, Milan Radovich, Lang Li, Laura Gardner, Dongbing Lai, Tatiana Foroud, and Kathy D. Miller, Indiana University School of Medicine, Indianapolis, IN; Anne O’Neill, Dana Farber Cancer Institute–ECOG-ACRIN Biostatistics Center, Boston, MA; Joseph A. Sparano, Albert Einstein University, Bronx, NY; and George W. Sledge Jr, Stanford University, Stanford, CA
| | - Lang Li
- Bryan P. Schneider, Fei Shen, Guanglong Jiang, Milan Radovich, Lang Li, Laura Gardner, Dongbing Lai, Tatiana Foroud, and Kathy D. Miller, Indiana University School of Medicine, Indianapolis, IN; Anne O’Neill, Dana Farber Cancer Institute–ECOG-ACRIN Biostatistics Center, Boston, MA; Joseph A. Sparano, Albert Einstein University, Bronx, NY; and George W. Sledge Jr, Stanford University, Stanford, CA
| | - Laura Gardner
- Bryan P. Schneider, Fei Shen, Guanglong Jiang, Milan Radovich, Lang Li, Laura Gardner, Dongbing Lai, Tatiana Foroud, and Kathy D. Miller, Indiana University School of Medicine, Indianapolis, IN; Anne O’Neill, Dana Farber Cancer Institute–ECOG-ACRIN Biostatistics Center, Boston, MA; Joseph A. Sparano, Albert Einstein University, Bronx, NY; and George W. Sledge Jr, Stanford University, Stanford, CA
| | - Dongbing Lai
- Bryan P. Schneider, Fei Shen, Guanglong Jiang, Milan Radovich, Lang Li, Laura Gardner, Dongbing Lai, Tatiana Foroud, and Kathy D. Miller, Indiana University School of Medicine, Indianapolis, IN; Anne O’Neill, Dana Farber Cancer Institute–ECOG-ACRIN Biostatistics Center, Boston, MA; Joseph A. Sparano, Albert Einstein University, Bronx, NY; and George W. Sledge Jr, Stanford University, Stanford, CA
| | - Tatiana Foroud
- Bryan P. Schneider, Fei Shen, Guanglong Jiang, Milan Radovich, Lang Li, Laura Gardner, Dongbing Lai, Tatiana Foroud, and Kathy D. Miller, Indiana University School of Medicine, Indianapolis, IN; Anne O’Neill, Dana Farber Cancer Institute–ECOG-ACRIN Biostatistics Center, Boston, MA; Joseph A. Sparano, Albert Einstein University, Bronx, NY; and George W. Sledge Jr, Stanford University, Stanford, CA
| | - Joseph A. Sparano
- Bryan P. Schneider, Fei Shen, Guanglong Jiang, Milan Radovich, Lang Li, Laura Gardner, Dongbing Lai, Tatiana Foroud, and Kathy D. Miller, Indiana University School of Medicine, Indianapolis, IN; Anne O’Neill, Dana Farber Cancer Institute–ECOG-ACRIN Biostatistics Center, Boston, MA; Joseph A. Sparano, Albert Einstein University, Bronx, NY; and George W. Sledge Jr, Stanford University, Stanford, CA
| | - George W. Sledge
- Bryan P. Schneider, Fei Shen, Guanglong Jiang, Milan Radovich, Lang Li, Laura Gardner, Dongbing Lai, Tatiana Foroud, and Kathy D. Miller, Indiana University School of Medicine, Indianapolis, IN; Anne O’Neill, Dana Farber Cancer Institute–ECOG-ACRIN Biostatistics Center, Boston, MA; Joseph A. Sparano, Albert Einstein University, Bronx, NY; and George W. Sledge Jr, Stanford University, Stanford, CA
| | - Kathy D. Miller
- Bryan P. Schneider, Fei Shen, Guanglong Jiang, Milan Radovich, Lang Li, Laura Gardner, Dongbing Lai, Tatiana Foroud, and Kathy D. Miller, Indiana University School of Medicine, Indianapolis, IN; Anne O’Neill, Dana Farber Cancer Institute–ECOG-ACRIN Biostatistics Center, Boston, MA; Joseph A. Sparano, Albert Einstein University, Bronx, NY; and George W. Sledge Jr, Stanford University, Stanford, CA
| |
Collapse
|
11
|
De Klerk C, Du Plessis G, Fourie JJ, O’Neill A, Smit SJA, Joubert G. The eventual outcome of patients who had lower limb amputations due to peripheral vascular disease at Pelonomi Hospital, Bloemfontein. S Afr Fam Pract (2004) 2017. [DOI: 10.1080/20786190.2016.1248145] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
Affiliation(s)
- C De Klerk
- Faculty of Health Sciences, School of Medicine, University of the Free State, Bloemfontein, South Africa
| | - G Du Plessis
- Faculty of Health Sciences, School of Medicine, University of the Free State, Bloemfontein, South Africa
| | - JJ Fourie
- Faculty of Health Sciences, School of Medicine, University of the Free State, Bloemfontein, South Africa
| | - A O’Neill
- Faculty of Health Sciences, School of Medicine, University of the Free State, Bloemfontein, South Africa
| | - SJA Smit
- Faculty of Health Sciences, Department of Surgery, University of the Free State, Bloemfontein, South Africa
| | - G Joubert
- Faculty of Health Sciences, Department of Biostatistics, University of the Free State, Bloemfontein, South Africa
| |
Collapse
|
12
|
Gonçalves A, Santos R, O’Neill A, Escada P, Fialho G, Caria H. Caratterizzazione della mutazione SLC26A4 c.918+2T>C e report di una nuova variante potenzialmente a rischio. Acta Otorhinolaryngol Ital 2016; 36:233-8. [PMID: 27214836 PMCID: PMC4977012 DOI: 10.14639/0392-100x-889] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/22/2015] [Accepted: 11/28/2015] [Indexed: 12/02/2022]
Abstract
Pendred syndrome (PS) is the second most common type of autosomal recessive syndromic hearing loss (HL). It is characterised by sensorineural HL and goiter with occasional hypothyroidism. These features are generally accompanied by malformations of the inner ear, as enlarged vestibular aqueduct (EVA). In about 50% of probands, mutations in the SLC26A4 gene are the cause of the disease. Here we report the case of a Portuguese female, aged 47, presenting with severe to profound HL and hypothyroidism. Her mother and sister, both deceased, had suffered from HL and goiter. By MRI and CT, an enlarged vestibular aqueduct and endolymphatic sac were observed. Molecular study of the patient included screening for GJB2 coding mutations and GJB6 common deletions followed by screening of all SLC26A4 exons, as well as intronic regions 8 and 14. Mutation c.918+2T>C was found for the first time in homozygosity in the intronic region 7 of the SLC26A4 gene. Whilst sequencing the control samples, a novel mutation c.821C>G was found in heterozygosity in the exon 7 of SLC26A4 gene and was predicted to be damaging. This study thus led to the finding of two novel SLC26A4 genotypes and provides new insight on the phenotypic features associated with PS.
Collapse
Affiliation(s)
- A.C. Gonçalves
- BioISI - Biosystems & Integrative Sciences Institute, Faculty of Science of the University of Lisbon, Portugal, * Present address: UCL Ear Institute, London, United Kingdom
| | - R. Santos
- ENT-CHLO, HEM, ENT Service, Centro Hospitalar de Lisboa Ocidental EPE, Egas Moniz Hospital, Portugal
| | - A. O’Neill
- ENT-CHLO, HEM, ENT Service, Centro Hospitalar de Lisboa Ocidental EPE, Egas Moniz Hospital, Portugal
- FCM/UNL, Department of Anatomy, Nova Medical School, New University of Lisbon, Portugal
| | - P. Escada
- ENT-CHLO, HEM, ENT Service, Centro Hospitalar de Lisboa Ocidental EPE, Egas Moniz Hospital, Portugal
| | - G. Fialho
- BioISI - Biosystems & Integrative Sciences Institute, Faculty of Science of the University of Lisbon, Portugal, * Present address: UCL Ear Institute, London, United Kingdom
| | - H. Caria
- BioISI - Biosystems & Integrative Sciences Institute, Faculty of Science of the University of Lisbon, Portugal, * Present address: UCL Ear Institute, London, United Kingdom
- ESS/IPS, School of Health, Polytechnic Institute of Setúbal, Portugal
| |
Collapse
|
13
|
Limaye S, Riley S, Zhao S, O’Neill A, Posner M, Adkins D, Jaffa Z, Clark J, Haddad R. A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN). Oral Oncol 2013; 49:835-41. [DOI: 10.1016/j.oraloncology.2013.04.010] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2013] [Revised: 04/24/2013] [Accepted: 04/26/2013] [Indexed: 11/25/2022]
|
14
|
Abstract
Our objective was to better understand the values and ethical dilemmas surrounding advance care planning through stories told by registered nurses and licensed social workers, who were employed as care managers within Area Agencies on Aging. We conducted eight focus groups in which care managers were invited to tell their stories and answer open-ended questions focusing on their interactions with consumers receiving home-based long-term care. Using narrative analysis to understand how our participants thought through particular experiences and what they valued, we identified seven themes representative of their work with consumers and families: humility, respect, responsibilities, boundaries, empowerment, courage, and veracity.
Collapse
|
15
|
Schwesig D, Borchers U, Chancerelle L, Dulio V, Eriksson U, Farré M, Goksoyr A, Lamoree M, Leonards P, Wegener JW, Lepom P, Leverett D, O’Neill A, Robinson R, Silharova K, Tolgyessy P, Slobodnik J, Tutundjian R, Westwood D. A harmonized European framework for method validation to support research on emerging pollutants. Trends Analyt Chem 2011. [DOI: 10.1016/j.trac.2011.03.015] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
16
|
Van Aggelen G, Ankley GT, Baldwin WS, Bearden DW, Benson WH, Chipman JK, Collette TW, Craft JA, Denslow ND, Embry MR, Falciani F, George SG, Helbing CC, Hoekstra PF, Iguchi T, Kagami Y, Katsiadaki I, Kille P, Liu L, Lord PG, McIntyre T, O’Neill A, Osachoff H, Perkins EJ, Santos EM, Skirrow RC, Snape JR, Tyler CR, Versteeg D, Viant MR, Volz DC, Williams TD, Yu L. Integrating omic technologies into aquatic ecological risk assessment and environmental monitoring: hurdles, achievements, and future outlook. Environ Health Perspect 2010; 118:1-5. [PMID: 20056575 PMCID: PMC2831950 DOI: 10.1289/ehp.0900985] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/15/2009] [Accepted: 08/17/2009] [Indexed: 05/20/2023]
Abstract
BACKGROUND In this commentary we present the findings from an international consortium on fish toxicogenomics sponsored by the U.K. Natural Environment Research Council (Fish Toxicogenomics-Moving into Regulation and Monitoring, held 21-23 April 2008 at the Pacific Environmental Science Centre, Vancouver, BC, Canada). OBJECTIVES The consortium from government agencies, academia, and industry addressed three topics: progress in ecotoxicogenomics, regulatory perspectives on roadblocks for practical implementation of toxicogenomics into risk assessment, and dealing with variability in data sets. DISCUSSION Participants noted that examples of successful application of omic technologies have been identified, but critical studies are needed to relate molecular changes to ecological adverse outcome. Participants made recommendations for the management of technical and biological variation. They also stressed the need for enhanced interdisciplinary training and communication as well as considerable investment into the generation and curation of appropriate reference omic data. CONCLUSIONS The participants concluded that, although there are hurdles to pass on the road to regulatory acceptance, omics technologies are already useful for elucidating modes of action of toxicants and can contribute to the risk assessment process as part of a weight-of-evidence approach.
Collapse
Affiliation(s)
- Graham Van Aggelen
- Environment Canada, Pacific Environmental Science Centre, Vancouver, British Columbia, Canada
| | | | | | - Daniel W. Bearden
- National Institute of Standards and Technology, Hollings Marine Laboratory, Charleston, South Carolina, USA
| | - William H. Benson
- U.S. Environmental Protection Agency, Gulf Ecology Division, Gulf Breeze, Florida, USA
| | - J. Kevin Chipman
- The University of Birmingham, Birmingham, West Midlands, United Kingdom
- Address correspondence to J.K. Chipman, School of Biosciences, University Rd. West, The University of Birmingham, Birmingham, B15 2TT, UK. Telephone: 44-121-414-5422. Fax: 44-121-414-5925. E-mail:
| | | | - John A. Craft
- Glasgow Caledonian University, Glasgow, Scotland, United Kingdom
| | | | - Michael R. Embry
- Health and Environmental Sciences Institute, Washington, DC, USA
| | | | | | - Caren C. Helbing
- University of Victoria, Greater Victoria, British Columbia, Canada
| | | | - Taisen Iguchi
- Okazaki National Research Institutes, Okazaki, Aichi, Japan
| | | | - Ioanna Katsiadaki
- Centre for Environment, Fisheries and Aquaculture Science, Weymouth, Dorset, United Kingdom
| | - Peter Kille
- Cardiff University, Cardiff, Wales, United Kingdom
| | - Li Liu
- University of Florida, Gainesville, Florida, USA
| | | | - Terry McIntyre
- Environment Canada, Pacific Environmental Science Centre, Vancouver, British Columbia, Canada
| | | | - Heather Osachoff
- Environment Canada, Pacific Environmental Science Centre, Vancouver, British Columbia, Canada
| | - Ed J. Perkins
- U.S. Army Corps of Engineers, Vicksburg, Mississippi, USA
| | | | - Rachel C. Skirrow
- Environment Canada, Pacific Environmental Science Centre, Vancouver, British Columbia, Canada
| | - Jason R. Snape
- Astrazeneca, Brixham Environmental Laboratory, Devon, United Kingdom
| | | | | | - Mark R. Viant
- The University of Birmingham, Birmingham, West Midlands, United Kingdom
| | - David C. Volz
- Syngenta Crop Protection Inc., Greensboro, North Carolina, USA
| | - Tim D. Williams
- The University of Birmingham, Birmingham, West Midlands, United Kingdom
| | - Lorraine Yu
- Environment Canada, Pacific Environmental Science Centre, Vancouver, British Columbia, Canada
| |
Collapse
|
17
|
Bhatt RS, Norden-Zfoni A, O’Neill A, Zurita AJ, Wu H, Prox D, Atkins MB, Heymach JV. Circulating endothelial cells are a potential biomarker for patients with renal cell carcinoma (RCC) with and without von Hippel Lindau (VHL) syndrome. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.5098] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
18
|
Moulder SL, O’Neill A, Arteaga C, Pins M, Sparano J, Sledge G, Davidson N. Final Results of ECOG1100: A phase I/II study of combined blockade of the ErbB receptor network in patients with HER2- overexpressing metastatic breast cancer (MBC). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.1033] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1033 Background: Activation of EGF receptor has been associated with resistance to trastuzumab in breast cancer cell lines. EGFR tyrosine kinase inhibitors inhibit HER2 phosphorylation and synergize with trastuzumab in HER2+ cell lines that co-express EGFR. Methods: Pts with MBC and HER2 overexpression by immunohistochemistry (3+) and/or HER2 gene-amplification by FISH, 0–2 prior chemotherapy regimens for met disease, LVEF 50%, and no prior trastuzumab were treated with trastuzumab 2 mg/kg/wk and gefitinib 250- 500 mg/day until disease progression, unacceptable toxicity or withdrawal of consent. The phase I portion of the trial used a 3+3 design to determine MTD. In the phase II portion of the trial, patients were stratified based upon prior chemotherapy exposure (Group 1= no prior exposure to chemotherapy, Group 2= prior exposure to 1–2 chemotherapy regimens). Response measured using RECIST criteria. The primary endpoint was to increase proportion progression free from 50 to 65% at 6 months in Group 1 and from 50 to 70% at 3 months in Group 2. Results: Phase I: DLT (Grade 3 diarrhea) occurred in 2/3 patients treated at the 500 mg/day dose level of gefitinib in combination with weekly trastuzumab. 0/3 patients treated at the 250 mg/day dose level experienced DLT. This was considered MTD and was the dose selected for the Phase II portion of the trial. Phase II: 36 eligible pts were enrolled. Most patients were ECOG PS of 0 and had visceral organ involvement. Of the patients enrolled in Group 1, one pt achieved a CR, one PR and 7 had SD (≥ 24 weeks). Median time to progression (TTP) was 2.9 months (95% CI, 2.5–4). In Group 2 no responses were observed with a median TTP of 2.5 months (95% CI, 1.5- 2.7). Most common severe toxicities were rash (grade 3, 14%) and diarrhea (grade 3, 30%). No grade 3 cardiac toxicity was encountered. Conclusions: Trastuzumab in combination with gefitinib at doses of 250 mg/day demonstrated an acceptable toxicity profile; however, during planned interim analysis, the TTP did not meet predetermined statistical endpoints required for study continuation. These results do not support the further use of this combination and have implications for other trials using trastuzumab and EGFR TK inhibitors simultaneously. [Table: see text]
Collapse
Affiliation(s)
- S. L. Moulder
- MD Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; Northwestern University, Chicago, IL; Montefiore Medical Center, New York, NY; Indiana University Medical Center, Indianapolis, IN; John Hopkins University, Baltimore, MD; Eastern Cooperative Oncology Group
| | - A. O’Neill
- MD Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; Northwestern University, Chicago, IL; Montefiore Medical Center, New York, NY; Indiana University Medical Center, Indianapolis, IN; John Hopkins University, Baltimore, MD; Eastern Cooperative Oncology Group
| | - C. Arteaga
- MD Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; Northwestern University, Chicago, IL; Montefiore Medical Center, New York, NY; Indiana University Medical Center, Indianapolis, IN; John Hopkins University, Baltimore, MD; Eastern Cooperative Oncology Group
| | - M. Pins
- MD Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; Northwestern University, Chicago, IL; Montefiore Medical Center, New York, NY; Indiana University Medical Center, Indianapolis, IN; John Hopkins University, Baltimore, MD; Eastern Cooperative Oncology Group
| | - J. Sparano
- MD Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; Northwestern University, Chicago, IL; Montefiore Medical Center, New York, NY; Indiana University Medical Center, Indianapolis, IN; John Hopkins University, Baltimore, MD; Eastern Cooperative Oncology Group
| | - G. Sledge
- MD Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; Northwestern University, Chicago, IL; Montefiore Medical Center, New York, NY; Indiana University Medical Center, Indianapolis, IN; John Hopkins University, Baltimore, MD; Eastern Cooperative Oncology Group
| | - N. Davidson
- MD Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; Northwestern University, Chicago, IL; Montefiore Medical Center, New York, NY; Indiana University Medical Center, Indianapolis, IN; John Hopkins University, Baltimore, MD; Eastern Cooperative Oncology Group
| |
Collapse
|
19
|
Kesari S, Schiff D, Doherty L, Gigas D, Batchelor T, Muzikansky A, O’Neill A, Drappatz J, Kieran M, Wen PY. Phase II study of antiangiogenic (metronomic) chemotherapy for recurrent malignant gliomas. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.1569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1569 Background: There is preclinical evidence that continuous low-dose chemotherapy may inhibit tumor endothelial proliferation and prevent tumor growth (Browder et al Cancer Res 2000;60:1878). Methods: We conducted a phase II study of continuous low-dose etoposide (VP-16), alternating with cyclophosphamide (CP), in combination with thalidomide (T) and celecoxib (C) in adult patients with recurrent malignant gliomas. There was no limit on the number of prior therapies. Patients received VP-16 [35 mg/m2 (maximum 100 mg) daily for 21 days] alternating with CP [2 mg/kg (maximum 100 mg/day) for 21 days]. Thalidomide was started at 200 mg daily and increased by 100 mg weekly to a maximum of 1200 mg/day, as tolerated. Celecoxib was started at 200 mg twice daily and increased to 400 mg twice daily. MRIs were performed every 6 weeks. Patients were treated until tumor progression or development of unacceptable toxicity. Serum was collected for measurement of angiogenic peptides. Results: 48 patients were enrolled (15 female, 33 male). 28 had glioblastomas (GBM); 20 had anaplastic gliomas (AG). Median age was 53 years (range 33–74); median KPS was 70 (range 60–100). Patients had average of 2.1 prior chemotherapies; 33% had 3 or more prior chemotherapies. Toxicities included neutropenia (8 G3, 8 G4), leukopenia (13 G3, 8 G4), lymphopenia (26 G3), anemia (1 G3), thrombocytopenia (1 G3); nausea (1 G3), vomiting (3 G3), constipation (5 G3; 2 G4), colitis (2 G4), rash (1 G3), dizziness (1 G3); hypoxia (1 G3), and infection (2 G3). 2 patients had DVT and 6 had pulmonary emboli. There were no treatment related deaths. Fatigue was common but usually mild. 12% of patients had PR, 59% had SD, 29% progressed at their first scan. For GBM patients, median progression-free survival (PFS) was 11 weeks, 6 month-PFS was 9% and median survival was 21 weeks. For AG patients, median PFS was 14 weeks; 6 month-PFS was 26% and median survival was 41.5 weeks. Correlation of angiogenic peptide levels and response will be reported. Conclusions: Although there were some responders this regimen did not significantly improve survival in this heavily pretreated group of patients. However, further studies combining metronomic chemotherapy with more potent angiogenesis inhibitors such as lenalidomide or VEGFR inhibitors may be warranted. [Table: see text]
Collapse
Affiliation(s)
- S. Kesari
- Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Charlottesville, VA; Massachusetts General Hospital, Boston, MA; Children’s Hospital, Boston, MA
| | - D. Schiff
- Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Charlottesville, VA; Massachusetts General Hospital, Boston, MA; Children’s Hospital, Boston, MA
| | - L. Doherty
- Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Charlottesville, VA; Massachusetts General Hospital, Boston, MA; Children’s Hospital, Boston, MA
| | - D. Gigas
- Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Charlottesville, VA; Massachusetts General Hospital, Boston, MA; Children’s Hospital, Boston, MA
| | - T. Batchelor
- Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Charlottesville, VA; Massachusetts General Hospital, Boston, MA; Children’s Hospital, Boston, MA
| | - A. Muzikansky
- Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Charlottesville, VA; Massachusetts General Hospital, Boston, MA; Children’s Hospital, Boston, MA
| | - A. O’Neill
- Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Charlottesville, VA; Massachusetts General Hospital, Boston, MA; Children’s Hospital, Boston, MA
| | - J. Drappatz
- Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Charlottesville, VA; Massachusetts General Hospital, Boston, MA; Children’s Hospital, Boston, MA
| | - M. Kieran
- Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Charlottesville, VA; Massachusetts General Hospital, Boston, MA; Children’s Hospital, Boston, MA
| | - P. Y. Wen
- Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Charlottesville, VA; Massachusetts General Hospital, Boston, MA; Children’s Hospital, Boston, MA
| |
Collapse
|
20
|
Goldstein LJ, O’Neill A, Sparano J, Perez E, Shulman L, Martino S, Davidson N. E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.512] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- L. J. Goldstein
- Fox Chase Cancer Ctr, Philadelphia, PA; Dana-Farber Cancer Inst, Boston, MA; Montefiore Medcl Ctr, Bronx, NY; Mayo Clinic, Jacksonville, FL; John Wayne Cancer Institute, Santa Monica, CA; Sidney Kimmel Cancer Ctr at Johns Hopkins, Baltimore, MD
| | - A. O’Neill
- Fox Chase Cancer Ctr, Philadelphia, PA; Dana-Farber Cancer Inst, Boston, MA; Montefiore Medcl Ctr, Bronx, NY; Mayo Clinic, Jacksonville, FL; John Wayne Cancer Institute, Santa Monica, CA; Sidney Kimmel Cancer Ctr at Johns Hopkins, Baltimore, MD
| | - J. Sparano
- Fox Chase Cancer Ctr, Philadelphia, PA; Dana-Farber Cancer Inst, Boston, MA; Montefiore Medcl Ctr, Bronx, NY; Mayo Clinic, Jacksonville, FL; John Wayne Cancer Institute, Santa Monica, CA; Sidney Kimmel Cancer Ctr at Johns Hopkins, Baltimore, MD
| | - E. Perez
- Fox Chase Cancer Ctr, Philadelphia, PA; Dana-Farber Cancer Inst, Boston, MA; Montefiore Medcl Ctr, Bronx, NY; Mayo Clinic, Jacksonville, FL; John Wayne Cancer Institute, Santa Monica, CA; Sidney Kimmel Cancer Ctr at Johns Hopkins, Baltimore, MD
| | - L. Shulman
- Fox Chase Cancer Ctr, Philadelphia, PA; Dana-Farber Cancer Inst, Boston, MA; Montefiore Medcl Ctr, Bronx, NY; Mayo Clinic, Jacksonville, FL; John Wayne Cancer Institute, Santa Monica, CA; Sidney Kimmel Cancer Ctr at Johns Hopkins, Baltimore, MD
| | - S. Martino
- Fox Chase Cancer Ctr, Philadelphia, PA; Dana-Farber Cancer Inst, Boston, MA; Montefiore Medcl Ctr, Bronx, NY; Mayo Clinic, Jacksonville, FL; John Wayne Cancer Institute, Santa Monica, CA; Sidney Kimmel Cancer Ctr at Johns Hopkins, Baltimore, MD
| | - N. Davidson
- Fox Chase Cancer Ctr, Philadelphia, PA; Dana-Farber Cancer Inst, Boston, MA; Montefiore Medcl Ctr, Bronx, NY; Mayo Clinic, Jacksonville, FL; John Wayne Cancer Institute, Santa Monica, CA; Sidney Kimmel Cancer Ctr at Johns Hopkins, Baltimore, MD
| |
Collapse
|
21
|
Hill ADK, Brady MS, Coit DG, Brennan M, Aherne N, Mukherjee A, Sarkar A, Coss A, Waldron R, Egan B, Grant DC, Barry MK, Gallagher CM, Traynor O, Hyland JMP, Younis F, Farah N, Lowry S, Gilooly M, Lee M, Walsh TN, Carton E, Mulligan ED, Caldwell MTP, Rana D, Ryan B, Mahmud N, Keeling N, Tanner WA, Keane FBV, McDonald G, Reynolds JV, McLaughlin R, Kelly CJ, Kay E, Bouchier-Hayes D, O’Neill S, Conroy E, O’Neill A, O’Connell R, Delaney C, Fitzpatrick JM, Watson RWG, Rasheed AM, Chen G, Kelly C, McDowell I, Cottel D, Bouchier-Hayes DJ, Leahy A, Kavanagh EG, Kell MR, Lyons A, Saporoschet I, Rodrick ML, Mannick JA, Lederer JA, McCourt M, Wang JH, Sookhai S, Neary P, Redmond HP. Waterford surgical october club and surgical section, royal academy of medicine joint surgical symposium at: Waterford regional hospital. Ir J Med Sci 1998. [DOI: 10.1007/bf02937973] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
22
|
Harbourne G, Byrne PC, Webb S, Hutchinson M, Parfrey NA, McMenamin M, O’Neill A, Gaffney E, Callagy G, Crowe J, O’Keane JC, Murphy J, Waters E, Madden M, Shanahan F, O’Sullivan G, Lee G, Brennan FK, Connolly CE, Cunney RJ, McNamara EB, Alansari N, Loo B, Smyth EG, Duggan C, O’Brien D, McCann SR, Lynch M, Cotter L, Cryan B, Greer P, Fanning S. Royal Academy of Medicine in Ireland Section of Pathology. Ir J Med Sci 1997. [DOI: 10.1007/bf02944250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|